Shares of Zafgen, Inc. (NASDAQ:ZFGN) have received an average recommendation of “Hold” from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and two have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $6.63.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research raised Zafgen from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research report on Saturday, November 11th. ValuEngine raised Zafgen from a “strong sell” rating to a “sell” rating in a research report on Monday, October 16th.
Shares of Zafgen (ZFGN) traded up $0.15 during trading hours on Friday, reaching $3.95. The company’s stock had a trading volume of 77,054 shares, compared to its average volume of 191,225. Zafgen has a 12 month low of $3.15 and a 12 month high of $5.46.
In related news, Director Frances K. Heller bought 10,000 shares of the firm’s stock in a transaction dated Friday, October 13th. The stock was bought at an average price of $3.90 per share, with a total value of $39,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 21.20% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its position in shares of Zafgen by 44.7% in the first quarter. Dimensional Fund Advisors LP now owns 443,311 shares of the biopharmaceutical company’s stock worth $2,066,000 after buying an additional 136,849 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Zafgen by 1,701.5% in the second quarter. Goldman Sachs Group Inc. now owns 197,287 shares of the biopharmaceutical company’s stock worth $692,000 after buying an additional 186,336 shares during the period. LMR Partners LLP purchased a new position in Zafgen in the second quarter valued at about $299,000. Mangrove Partners purchased a new position in Zafgen in the third quarter valued at about $1,971,000. Finally, OxFORD Asset Management LLP purchased a new position in Zafgen in the second quarter valued at about $364,000. 48.60% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Zafgen, Inc. (ZFGN) Receives Consensus Rating of “Hold” from Analysts” was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.com-unik.info/2017/12/20/zafgen-inc-zfgn-receives-consensus-rating-of-hold-from-analysts.html.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
What are top analysts saying about Zafgen? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zafgen and related companies.